Aspire Biopharma Closes $30M DCS Deal, Adding $200M+ Revenue Stream
ASBP has more than doubled off its 52-week low of $3.309 on light trading volume (0.1× avg).
Summary
Aspire Biopharma completed its $30 million acquisition of Dura Driver Control Systems, a tier-one automotive supplier with $209.5 million in 2025 revenue and $22.3 million adjusted EBITDA. The deal, first announced in June, transforms the micro-cap biopharma into a diversified company with immediate scale. A new $22.5 million credit facility partly funded the purchase. DCS brings 11 global facilities, over 50 customers, and a portfolio of 275+ parts. The acquisition is expected to be immediately accretive to revenue, earnings, and cash flow. This follows a series of dilutive financing moves and a reverse split, but the DCS financials provide a tangible operating base. Watch for integration updates and the impact on Aspire's legacy drug-delivery pipeline.
Updates
· SEC 8-K — Aspire issued $3.75M principal amount of convertible notes for $3M purchase price, reflecting 20% original issue discount, convertible at $8.00 per share.
At the time of this announcement, ASBP was trading at $7.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10M. The 52-week trading range was $3.31 to $1,050.36. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.